And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda includes escorting Mrs. Pharmalot to another installment in our “Let’s-see-them-before-they-die” concert series. Otherwise, we plan to catch up on our reading and a few sundry chores. And what about you? This could be a good time to start organizing your taxes. Maybe you want to catch up on some of the moving pictures that are generating notice. Or you could simply plan the rest of your life. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

Johnson & Johnson (JNJ) has pulled out of the race to buy the Pfizer (PFE) consumer health business, leaving GlaxoSmithKline (GSK) and Reckitt Benckiser (RBGPF) among those preparing bids, according to Reuters. Bidders have until Feb. 1 to submit their non-binding offers for the unit, which had sales of about $3.4 billion in 2016 and makes the Advil painkiller, Centrum multivitamins, and Chapstick lip balm.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy